Clinical features of ISCMs, per-patient basis (n = 49 patients)
| Feature | Prevalence |
|---|---|
| Sex | |
| Female | 26 (53%) |
| Primary malignancy | |
| Lung carcinoma | 24 (49%) |
| Breast carcinoma | 7 (14%) |
| Melanoma | 5 (10%) |
| CNS origin | 4 (8%) |
| Renal cell carcinoma | 3 (6%) |
| Other | 6 (12%) |
| Timing of primary tumor diagnosis | |
| ISCM presentation preceded primary tumor diagnosis | 10 (20%) |
| ISCM diagnosis preceded primary tumor diagnosis | 5 (10%) |
| Dominant presenting symptoms | |
| Weakness | 28 (57%) |
| Sensory symptoms | 8 (16%) |
| Bowel and/or bladder dysfunction | 5 (10%) |
| Pain | 4 (8%) |
| Asymptomatic | 4 (8%) |
| Time interval, median (range) | |
| Duration of symptoms at clinical presentation (n = 44) | 2 weeks (0.1–32) |
| Primary tumor diagnosis to ISCM presentation (n = 38) | 1.8 years (0–19.3) |
| Primary tumor diagnosis to ISCM diagnosis (n = 44) | 1.6 years (0–19.5) |